SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 3 filers reported holding SAGE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,698,870 | -48.8% | 1,005,776 | +17.0% | 1.96% | -40.0% |
| Q2 2023 | $40,414,489 | +12.1% | 859,517 | 0.0% | 3.26% | +9.3% |
| Q1 2023 | $36,065,333 | +10.4% | 859,517 | +0.4% | 2.99% | +7.3% |
| Q4 2022 | $32,667,558 | -2.0% | 856,517 | +0.6% | 2.78% | +5.7% |
| Q3 2022 | $33,341,000 | +21.2% | 851,409 | 0.0% | 2.64% | +10.0% |
| Q2 2022 | $27,501,000 | -2.5% | 851,409 | -0.0% | 2.40% | +10.0% |
| Q1 2022 | $28,192,000 | -15.2% | 851,719 | +9.0% | 2.18% | +2.6% |
| Q4 2021 | $33,255,000 | +21.5% | 781,730 | +26.5% | 2.12% | +28.6% |
| Q3 2021 | $27,380,000 | -19.7% | 617,930 | +2.9% | 1.65% | -12.1% |
| Q2 2021 | $34,114,000 | -24.1% | 600,500 | 0.0% | 1.88% | -26.6% |
| Q1 2021 | $44,947,000 | -12.0% | 600,500 | +1.7% | 2.56% | -4.3% |
| Q4 2020 | $51,058,000 | +41.5% | 590,200 | 0.0% | 2.68% | +35.2% |
| Q3 2020 | $36,073,000 | +50.8% | 590,200 | +2.6% | 1.98% | +37.9% |
| Q2 2020 | $23,917,000 | +41.9% | 575,200 | -2.0% | 1.44% | +1.8% |
| Q1 2020 | $16,849,000 | -64.3% | 586,674 | -10.2% | 1.41% | -45.7% |
| Q4 2019 | $47,183,000 | -50.6% | 653,594 | -4.0% | 2.60% | -59.2% |
| Q3 2019 | $95,523,000 | -34.4% | 680,894 | -14.4% | 6.36% | -10.1% |
| Q2 2019 | $145,562,000 | +6.7% | 795,031 | -7.3% | 7.08% | +24.4% |
| Q1 2019 | $136,414,000 | +67.3% | 857,681 | +0.8% | 5.69% | +31.2% |
| Q4 2018 | $81,515,000 | -31.3% | 850,977 | +1.3% | 4.34% | -9.6% |
| Q3 2018 | $118,703,000 | -8.9% | 840,372 | +0.9% | 4.80% | -7.9% |
| Q2 2018 | $130,317,000 | -1.1% | 832,536 | +1.7% | 5.21% | -7.6% |
| Q1 2018 | $131,809,000 | -1.3% | 818,331 | +0.9% | 5.64% | -2.0% |
| Q4 2017 | $133,548,000 | +172.3% | 810,806 | +3.0% | 5.75% | +178.4% |
| Q3 2017 | $49,046,000 | -40.4% | 787,251 | -23.8% | 2.07% | -46.2% |
| Q2 2017 | $82,270,000 | +5.0% | 1,033,025 | -6.3% | 3.84% | +3.8% |
| Q1 2017 | $78,316,000 | +51.9% | 1,101,951 | +9.1% | 3.70% | +25.8% |
| Q4 2016 | $51,567,000 | +24.1% | 1,009,930 | +12.0% | 2.94% | +21.9% |
| Q3 2016 | $41,539,000 | +229.9% | 902,051 | +115.9% | 2.41% | +153.7% |
| Q2 2016 | $12,591,000 | – | 417,878 | – | 0.95% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |